BofA lowered the firm’s price target on Apellis (APLS) to $44 from $47 and keeps a Buy rating on the shares post the Q4 report. The company expects Q1 revenue to be lower relative to Q4 but underscored that it remains confident in seeing overall growth in 2025, the analyst tells investors in a research note. The firm thinks Apellis’ geographic atrophy market opportunity remains undervalued and sees several potential tailwinds for Syfovre in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $30 from $31 at Morgan Stanley
- Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
- Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
- Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
- Apellis Pharmaceuticals Reports Strong 2024 Growth